Literature DB >> 7668823

Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease.

T B Freeman1, C W Olanow, R A Hauser, G M Nauert, D A Smith, C V Borlongan, P R Sanberg, D A Holt, J H Kordower, F J Vingerhoets.   

Abstract

We performed fetal nigral transplantations in 4 Parkinson's disease (PD) patients. Solid grafts were bilaterally implanted into the postcommissural putamen using 3 to 4 donors per side aged 6 1/2 to 9 weeks postconception. Transplant deposits were separated by no more than 5 mm in three dimensions. Cyclosporine was employed for a total of 6 months. Patients were evaluated at baseline and at 1, 3, and 6 months postoperatively. Striatal 18-fluorodopa uptake was assessed by positron emission tomography at baseline and at 6 months postoperatively. The procedure was well tolerated in all patients. One patient had a clinically asymptomatic superficial cortical hemorrhage along the needle tract and a second had transient postoperative confusion and hallucinations. All patients experienced clinically meaningful benefit. Significant improvement (p < 0.05) was detected in total UPDRS score during the "off" state, Schwab-England disability score during the "off" state, percent "off" time, and percent "on" time with dyskinesia. Increased striatal fluorodopa uptake was observed bilaterally in each patient, with mean increases of 53% on the right (p = 0.01) and 33% on the left (p = 0.08). Our study demonstrated clear and consistent improvement in clinical features and striatal fluorodopa uptake following fetal tissue transplantation in patients with advanced PD whose condition was not improved preoperatively by drug manipulation. These preliminary results are encouraging and support further studies to evaluate grafting strategies as a therapy for PD.

Entities:  

Mesh:

Year:  1995        PMID: 7668823     DOI: 10.1002/ana.410380307

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  50 in total

1.  Novel therapies in the search for a cure for Huntington's disease.

Authors:  M F Beal; P Hantraye
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

2.  Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease?

Authors:  Curt R Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 3.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

4.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

Review 5.  The design of clinical trials for cell transplantation into the central nervous system.

Authors:  Pierre Cesaro
Journal:  NeuroRx       Date:  2004-10

Review 6.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

Review 7.  Evidence from clinical trials: can we do better?

Authors:  Andrew D Siderowf
Journal:  NeuroRx       Date:  2004-07

Review 8.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

Review 9.  Cell-based therapies in Parkinson's disease.

Authors:  Paul Greene
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

Review 10.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.